JP2020524149A - Ａｐｒｉｌ−ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法 - Google Patents

Ａｐｒｉｌ−ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法 Download PDF

Info

Publication number
JP2020524149A
JP2020524149A JP2019569878A JP2019569878A JP2020524149A JP 2020524149 A JP2020524149 A JP 2020524149A JP 2019569878 A JP2019569878 A JP 2019569878A JP 2019569878 A JP2019569878 A JP 2019569878A JP 2020524149 A JP2020524149 A JP 2020524149A
Authority
JP
Japan
Prior art keywords
treg
breg
cell
agent
april
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019569878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524149A5 (enExample
Inventor
ケネス シー． アンダーソン，
ケネス シー． アンダーソン，
ユー−ズー タイ，
ユー−ズー タイ，
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド, デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2020524149A publication Critical patent/JP2020524149A/ja
Publication of JP2020524149A5 publication Critical patent/JP2020524149A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019569878A 2017-06-20 2018-06-20 Ａｐｒｉｌ−ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法 Pending JP2020524149A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762522167P 2017-06-20 2017-06-20
US62/522,167 2017-06-20
US201762573264P 2017-10-17 2017-10-17
US62/573,264 2017-10-17
US201862677265P 2018-05-29 2018-05-29
US62/677,265 2018-05-29
PCT/US2018/038490 WO2018236995A2 (en) 2017-06-20 2018-06-20 Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction

Publications (2)

Publication Number Publication Date
JP2020524149A true JP2020524149A (ja) 2020-08-13
JP2020524149A5 JP2020524149A5 (enExample) 2021-07-29

Family

ID=64735842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569878A Pending JP2020524149A (ja) 2017-06-20 2018-06-20 Ａｐｒｉｌ−ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法

Country Status (7)

Country Link
US (1) US12005073B2 (enExample)
EP (1) EP3642243A4 (enExample)
JP (1) JP2020524149A (enExample)
CN (1) CN110945030A (enExample)
AU (1) AU2018289493B2 (enExample)
CA (1) CA3064632A1 (enExample)
WO (1) WO2018236995A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11435370B2 (en) * 2017-01-16 2022-09-06 Shimadzu Corporation Data analying device and program for data analysis
AU2018289493B2 (en) 2017-06-20 2025-07-03 Dana-Farber Cancer Institute, Inc. Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
PH12021552986A1 (en) * 2019-05-31 2023-08-14 Dana Farber Cancer Inst Inc Combination therapy
CN115812077A (zh) 2020-05-08 2023-03-17 高山免疫科学股份有限公司 April和baff抑制性免疫调节蛋白及其使用方法
CN113368262A (zh) * 2020-09-03 2021-09-10 上海易慕峰生物科技有限公司 通过实体肿瘤转移动物模型获取中间结果的方法
US20230310500A1 (en) * 2020-09-03 2023-10-05 Techno Craft Corporation Ltd. Use of Immune Killer Cell Against Circulating Tumor Cells in Solid Tumor Treatment
EP4221697A4 (en) * 2020-09-29 2024-11-20 Purdue Research Foundation Curcusone diterpenoids and uses thereof
CN113278619B (zh) * 2021-07-19 2021-10-15 广东省农业科学院动物科学研究所 双sgRNA、基因敲除载体、基因敲除STING基因的猪成纤维细胞系及其构建方法
CN114147343B (zh) * 2021-12-08 2024-08-16 西安中科微精光子科技股份有限公司 一种激光加工方法、系统及计算机存储介质
CN118126196B (zh) * 2024-03-06 2024-08-16 中国医学科学院基础医学研究所 一种具有包含taci融合蛋白的基因工程化外泌体及其制备方法和应用
CN120843525B (zh) * 2025-09-23 2025-12-09 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 特异结合人april的中和核酸适体及其在抑制抗体分泌中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047121A1 (en) * 2009-10-14 2011-04-21 Schering Corporation April antagonists and methods of use
WO2016110587A1 (en) * 2015-01-09 2016-07-14 Aduro Biotech Holdings, Europe B.V. Altered april binding antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
RU2322500C2 (ru) * 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
WO2010075249A2 (en) * 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102585016B (zh) 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
AU2018289493B2 (en) 2017-06-20 2025-07-03 Dana-Farber Cancer Institute, Inc. Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047121A1 (en) * 2009-10-14 2011-04-21 Schering Corporation April antagonists and methods of use
WO2016110587A1 (en) * 2015-01-09 2016-07-14 Aduro Biotech Holdings, Europe B.V. Altered april binding antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, 2016, VOL.128, NO.22, P.2112, JPN6022031425, ISSN: 0005358144 *
NATURE COMMUNICATIONS, 2015, VOL.6, NO.5997, PP.1-16, JPN6023005493, ISSN: 0005358146 *
NATURE IMMUNOLOGY, 2000, VOL.1, NO.3, PP.252-256, JPN6022031426, ISSN: 0005358145 *

Also Published As

Publication number Publication date
CA3064632A1 (en) 2018-12-27
WO2018236995A3 (en) 2019-01-31
US12005073B2 (en) 2024-06-11
EP3642243A2 (en) 2020-04-29
CN110945030A (zh) 2020-03-31
EP3642243A4 (en) 2021-04-28
AU2018289493B2 (en) 2025-07-03
WO2018236995A2 (en) 2018-12-27
AU2018289493A1 (en) 2019-12-12
US20210113605A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
US12005073B2 (en) Methods for modulating regulatory T cells, regulatory b cells, and immune responses using modulators of the april-taci interaction
JP2023529026A (ja) Ｍｈｃ－ｉ発現を調節するための方法及びその免疫療法の使用
US20170130271A1 (en) Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP4093513A1 (en) Uses of biomarkers for improving immunotherapy
US20180303922A1 (en) Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
US20200108066A1 (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
WO2018184003A1 (en) Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
WO2018148378A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
CN109689062B (zh) 使用抗PI3Kβ和抗免疫检查点药剂的组合治疗PTEN缺陷型上皮癌的方法
US11740242B2 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
US12109266B2 (en) Modulating gabarap to modulate immunogenic cell death
JP2019512271A (ja) Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
CA3091859A1 (en) Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof
US20200149042A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
US11852631B2 (en) Biomarkers predictive of anti-immune checkpoint response
AU2019227641B2 (en) Methods for treating cancer using combinations of anti-BTNL2 and immune checkpoint blockade agents
JP2025011250A (ja) 免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
US20220289854A1 (en) Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
AU2019257249B2 (en) KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
HK40028190A (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240401

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240705